Emerging Markets Sisu Global focuses on Hemafuse as a mechanical blood replacement solution in emerging markets such as Ghana, Kenya, India, and Tanzania, presenting a sales opportunity to regional hospital systems, NGOs, and government procurement programs seeking reliable access to blood transfusion alternatives.

Public Funding The company has secured non-dilutive grants from groups like USAID and VC funding from Revolutions' Rise of the Rest, indicating credibility with funders and potential for grant-aligned distribution partnerships, as well as opportunities to co-market with development initiatives.

Clinical Utility Hemafuse provides immediate, patient-captured blood access across trauma, obstetric, general, and orthopedic surgeries, which positions it as a cost-effective, life-saving device for high-need facilities facing blood supply challenges and donor limitations.

Growth Trajectory Recent press indicates a renewed push to scale Hemafuse internationally in 2024 after initial launch in 2018, suggesting a door-open window for distributors, integrators, and regional sales partners to accelerate market entry and adoption.

Technology & Support Sisu Global leverages lightweight, standards-based tech and a web presence to support deployment, offering a door for technology-enabled sales motions, maintenance service agreements, and local training partnerships with clinical engineers and hospital procurement teams.